[1] | Gudarzi MO, Dumesik DA, Chazenbalk G., Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7: 219-231. |
[2] | Gafurova F.A., Asatova M.M. Evaluation of the clinical efficacy of MHT in the appointment of menopausal hormone therapy in the perimenopausal period. Journal of Theoretical and Clinical Medicine, 2017; 4: 77-80. |
[3] | Gafurova F., Artikhodjaeva G., The hormonal disturbances, postmoropausalis and postmenopausal women. Abstract, 12th Congress of the European Society of Gynecology - ESG, 2017. |
[4] | Gafurova F. Menopause and the metabolic syndrome: clinical efficiency of hormone replacement therapy. Abstract, 12th Congress of the European Society of Gynecology - ESG, 2017. |
[5] | Asatov M.M., Gafurova F.A. The use of the drug for menopausal hormone therapy with drospirenone in the treatment of menopausal disorders in women. Journal of Theoretical and Clinical Medicine, 2017; 4: 80-82. |
[6] | Asatova M.M., Gafurova F.A. Effect of expression of the metabolic syndrome on the menopause. Abstract, 11th Congress of the European Society of Gynecology - ESG, 2015. |
[7] | Gafurova F., Asatova M.M. Factors affecting cardiovasculaf mortality risk in postmenopausal age women with stable arterial hypertension. Abstract, 12th Congress of the European Society of Gynecology - ESG, 2017. |
[8] | Luque-Ramirez M, Escobar-Morreale HF. Polycystic ovary syndrome as a paradigm of prehypertension, prediabest and predisposition. Curr Hypertens Rep., 2014; 16: 500. |
[9] | Rotterdam Expert Group on SPT consensus, sponsored by Rotterdam SPF. The revised 2003 consensus on diagnostic criteria and long-term health risks associated with polycystic ovary syndrome. Fertil Steril. 2004; 81: 19-25. |
[10] | Azziz R, Carmina E, Dewailly D, et al. Target group on the phenotype of polycystic ovary syndrome from the excess androgen family and PCOS. Criteria of androgenic excess and SPKO for polycystic ovary syndrome: a full report of the target group. Fertil Steril. 2009; 91: 456-488. |
[11] | Hsu MI. Changes in the PCOS phenotype with age. Steroids. 2013; 78: 761-766. |
[12] | Lobo R.A. Postmenopausal metabolic syndrome and the role of hormones. Maturitas. 2008; 60: 10-18. |
[13] | Brown ZA, Louwers YV, Fong SL, et al. The phenotype of polycystic ovary syndrome improves aging. Fertil Steril. 2011; 96: 1259-1265. |
[14] | Haoula Z, Salman M, Atiomo W. Evaluation of the link between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012; 27: 1327-1331. |
[15] | Alsamarai S, Adams JM, Murphy MK, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab. 2009; 94: 4961-4970. |
[16] | Puurunen J, Piltonen T, Morin-Papunen L, et al. Adverse hormonal, metabolic and inflammatory changes persist after menopause in women with PCOS. J Clin Endocrinol Metab. 2011; 96: 1827-1834. |
[17] | Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab. 2011; 96: 623-631. |
[18] | Livadas S, Kollias A, Panidis D, Diamanti-Kandarakis E. Various effects of aging on insulin resistance in women with obesity and obesity with polycystic ovary syndrome: data from 1345 women with the syndrome. Eur J Endocrinol. 2014; 171: 301-309. |
[19] | Krentz A. Yu., von Mühlen D., Barrett-Connor E. The search for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with a common cardiovascular disease. Menopause. 2007; 14: 284-292. |
[20] | Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menstruation and increased androgenic measurements with a high risk to worsen survival without cardiovascular events: the results of the National Institute of Health - the National Institute of Heart, Lung and Blood sponsored by the female ischemic syndrome. J Clin Endocrinol Metab. 2008; 93: 1276-1284. |
[21] | Kandaraki E., Kristakov S., Diamanti-Kandarakis E. Metabolic syndrome and polycystic ovary syndrome ... and vice versa. Ark Bras Endocrinol Metabol. 2009; 53: 227-237. |
[22] | Phillips GB, Jing T, Heymsfield SB. Does insulin resistance, visceral obesity or changes in sex hormones at the heart of the metabolic syndrome affect? Studies in women. Metabolism. 2008; 57: 838-844. |
[23] | Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of developing gynecological cancer: a systematic review. Reprod Biomed Online. 2009; 19: 398-405. |
[24] | Christakou C, Diamanti-Kandarakis E. Structural, biochemical, and unconventional markers of cardiovascular risk in PCOS. Curr Pharm Des. 2013; 19: 5764-5774. |
[25] | Gonzalez, F., Roit, NS, Minium, J., Kirwan, JP. Reactive oxygen oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91: 336-340. |
[26] | Guzik D.S. Cardiovascular risk in PCOS. J Clin Endocrinol Metab. 2004; 89: 3694-3695. |
[27] | Barry J.A., Aziziya MM, Khardiman P.J. The risk of developing endometrial cancer, ovarian cancer and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Update Hum Reprod. 2014; 20: 748-758. |
[28] | Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular diseases in women with polycystic ovary syndrome with prolonged observation: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600. |
[29] | Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular diseases and risk factors in women with PCOS in postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011; 96: 3794-3803. |
[30] | Fauser BC, Bouchard P. Uncertainty remains in women with PCOS with respect to an increase in the incidence of cardiovascular diseases in later life, despite the undeniable presence of several cardiovascular risk factors at a young age. J Clin Endocrinol Metab. 2011; 96: 3675-3677. |
[31] | Genazzani AR, Gadducci A, Gambacciani M, International Expert Workshop on Menopause. Controversial issues in climacteric medicine. Ii. Hormone replacement therapy and cancer. Maturitas. 2001; 40: 117-130. |